Insider Selling: Alignment Healthcare (NASDAQ:ALHC) Insider Sells $448,230.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Christopher Joyce sold 25,125 shares of Alignment Healthcare stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total transaction of $448,230.00. Following the transaction, the insider directly owned 323,464 shares of the company’s stock, valued at approximately $5,770,597.76. This trade represents a 7.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Alignment Healthcare Stock Performance

Shares of NASDAQ ALHC opened at $17.34 on Friday. The company’s fifty day moving average price is $20.44 and its 200 day moving average price is $18.80. Alignment Healthcare, Inc. has a 1 year low of $11.63 and a 1 year high of $23.87. The company has a market capitalization of $3.54 billion, a PE ratio of -1,732.27, a price-to-earnings-growth ratio of 2.54 and a beta of 1.18. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71.

Alignment Healthcare (NASDAQ:ALHC) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The firm’s revenue for the quarter was up 44.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.16) earnings per share. On average, research analysts predict that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Institutional Investors Weigh In On Alignment Healthcare

Large investors have recently bought and sold shares of the company. Allworth Financial LP raised its holdings in shares of Alignment Healthcare by 8.9% during the fourth quarter. Allworth Financial LP now owns 6,917 shares of the company’s stock valued at $137,000 after acquiring an additional 566 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in shares of Alignment Healthcare by 6.0% in the fourth quarter. State of Alaska Department of Revenue now owns 11,296 shares of the company’s stock worth $223,000 after acquiring an additional 636 shares during the last quarter. Integrated Wealth Concepts LLC increased its position in shares of Alignment Healthcare by 6.3% during the third quarter. Integrated Wealth Concepts LLC now owns 11,230 shares of the company’s stock worth $196,000 after purchasing an additional 665 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Alignment Healthcare by 87.7% during the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock worth $33,000 after purchasing an additional 773 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Alignment Healthcare by 2.3% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,752 shares of the company’s stock valued at $659,000 after purchasing an additional 844 shares during the last quarter. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

More Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Strong fundamentals — Alignment reported Q4 revenue of ~$1.01B and an EPS beat (‑$0.05 vs. consensus ‑$0.15) with revenue up ~44% YoY, which supports longer‑term growth expectations. Earnings Summary
• Positive Sentiment: Analyst bullishness — Multiple brokerages have raised price targets and maintain Buy/Overweight views (e.g., TD Cowen, JPMorgan, KeyCorp, Robert W. Baird), leaving a consensus analyst stance that is constructive for the stock. Analyst Coverage
• Neutral Sentiment: Short‑interest data published for March appears erroneous (shows 0 shares / NaN changes). Do not treat those figures as evidence of new short pressure until exchanges correct the data.
• Neutral Sentiment: High institutional ownership (~86%) can mute volatility from retail flows but also means institutional positioning matters for future moves; a Zacks comparison piece contrasts ALHC with peers for valuation context. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Secondary offering announced by a major shareholder — the planned secondary raises potential near‑term selling supply and is a clear negative for price action until the offering size and timing are known. Alignment Healthcare announces secondary offering by major shareholder
• Negative Sentiment: Clustered insider selling — several senior executives reported sales on Mar 18–19 (CEO John E. Kao: 73,046 shares; President Dawn Maroney: 36,749; COO Sebastian Burzacchi: 15,361; plus multiple other officers, and Robert Scavo sold 11,285). These simultaneous disposals (~tens of thousands of shares each at ~$17.84) create headline risk and likely contributed to today’s negative sentiment. Representative SEC filings: Kao — Kao SEC Filing, Scavo — Scavo SEC Filing

Analyst Ratings Changes

A number of research firms recently weighed in on ALHC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alignment Healthcare in a report on Wednesday, January 21st. KeyCorp reissued an “overweight” rating and issued a $28.00 price objective on shares of Alignment Healthcare in a report on Thursday, January 22nd. JPMorgan Chase & Co. boosted their price objective on Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Piper Sandler upped their target price on Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 6th. Finally, Robert W. Baird set a $28.00 target price on Alignment Healthcare in a research report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.56.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.